An open solution to improving research reproducibility
Academic and industry scientists collaborate on a new method to characterize research antibodiesStructural Genomics Consortium researchers at The Neuro (Montreal Neurological Institute-Hospital) of 麻豆AV, in collaboration with scientists from 11 major antibody manufacturers representing approximately 80 per cent of global renewable antibody production, have developed and standardized an Open Science platform to characterize research antibodies.
Open Science project funded for $1.5M
YCharOS antibody characterization platform addresses the 鈥渞eproducibility crisis鈥� in researchAn innovative research project led by researchers at The Neuro has been awarded $1.5M by the Government of Quebec through CQDM.
YCharOS is an innovative platform led by neuroscientists Peter McPherson and Carl Laflamme that validates antibody reagents for human proteins.
Recreating a hallmark of Parkinson's disease in human neurons
Scientists use stem cells to follow development of protein bodies characteristic of neurological diseaseLewy bodies are a hallmark of Parkinson's disease (PD) and other related neurological conditions. Understanding why and how they develop is critical to developing better treatments.
Open Science antibody characterization project receives $4-million grant
YCharOS is an independent quality assessment initiative to improve research results听An antibody characterization project with partners at The Neuro will be able to expand thanks to funding from G茅nome Qu茅bec.听听
YCharOS forms key industry advisory committee and releases first open data
Leading antibody reagent and knockout cell line manufacturers team up to address life science reproducibility crisis
YCharOS Inc., an open science company with the mission of characterizing commercially available antibody reagents for all human proteins, is pleased to announce the publication of its first characterization data and formation of its Industry Advisory Committee (IAC).
Improving research with more effective antibodies
Scientists demonstrate flaws in protein detection tools, and outline a solution
A new study points to the need for better antibody validation, and outlines a process that other labs can use to make sure the antibodies they work with function properly.
June is ALS Month
A look at the latest ALS research and clinical care at The Neuro
Amyotrophic lateral sclerosis (ALS) is a terrible disease with no known cure. Research at The Montreal Neurological Institute and Hospital (The Neuro) is uncovering data that could help find effective treatments for ALS.听
The Neuro and Thermo Fisher Scientific Partner to Fight Neurodegenerative Disease
Industry and academia to share expertise in effort to develop improved methods to produce and characterize antibodies and reagents for neurological research
ALS 鈥� Fostering awareness of a devastating disease
ALS takes away the patient鈥檚 motor functions one at a time, and the progress of finding effective drugs to counter its insidious effects has been slow. June is ALS Month, a good time to update the public on the latest developments in ALS research taking place at The Neuro.
The Montreal Neurological Institute and Hospital (The Neuro) is recognized as a leading Canadian centre for research into amyotrophic lateral sclerosis (ALS) as well as for its care of ALS patients.
Epileptic encephalopathy linked to protein trafficking gene
Researchers have linked a debilitating neurological disease in children to mutations in a gene that regulates neuronal development through control of protein movement within neuronal cells.
MNI researchers receive funding to study ARSACS
Two researchers at the Montreal Neurological Institute and Hospital (MNI) of 麻豆AV have received funding to study a devastating neurodegenerative disease that first appears in toddlers just as they are beginning to walk.
Major ALS Research Funding Announced
MNI scientists will study stem cells, genetic mutations to develop new treatments
Researchers at the Montreal Neurological Institute of 麻豆AV who are playing key roles in uncovering the mechanisms underlying ALS will share in $3.9 million in research funding, part of $4.5 million announced on Nov. 23 by the ALS Society of Canada in partnership with Brain Canada.
ALS Awareness Month 鈥� June 2016
The Neuro is recognized as a major Canadian center for ALS research and patient care. During June, designated ALS Month, The Neuro redoubles its efforts to inform the public and the media about amyotrophic lateral sclerosis (ALS), and urges all to help support ALS research.
Scientists and Clinicians at The Montreal Neurological Institute and Hospital receive funding for ALS research
The ALS Ice Bucket Challenge One Year Later
On November 19 2015, marking the anniversary of the announcement of the 2014 ALS Ice Bucket Challenge results and partnership between ALS Canada and Brain Canada, ALS Canada was at The Montreal Neurological Institute and Hospital 鈥� The Neuro, to announce the final recipients of their 2015 grant competition. Four researchers and clinicians at The Neuro were among those recipients for their groundbreaking work in the ALS research field.
ALS Awareness Month 鈥� June
As a major Canadian centre for amyotrophic lateral sclerosis (ALS) research and treatment, the Montreal Neurological Institute and Hospital - The Neuro, invites the public and the media to learn more about the disease and current research and treatments, to donate money for ALS research and to wear the national emblem of ALS in Canada, the blue cornflower, during ALS Awareness Month in June.
